Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Gross Profit: 2012-2024

Historic Gross Profit for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $373.9 million.

  • Amphastar Pharmaceuticals' Gross Profit fell 3.23% to $98.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $357.0 million, marking a year-over-year decrease of 6.86%. This contributed to the annual value of $373.9 million for FY2024, which is 6.47% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Gross Profit stood at $373.9 million for FY2024, which was up 6.47% from $351.1 million recorded in FY2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Gross Profit peaked at $373.9 million during FY2024, and registered a low of $143.3 million during FY2020.
  • For the 3-year period, Amphastar Pharmaceuticals' Gross Profit averaged around $324.6 million, with its median value being $351.1 million (2023).
  • Data for Amphastar Pharmaceuticals' Gross Profit shows a peak YoY surged of 41.09% (in 2023) over the last 5 years.
  • Amphastar Pharmaceuticals' Gross Profit (Yearly) stood at $143.3 million in 2020, then soared by 39.35% to $199.7 million in 2021, then increased by 24.59% to $248.9 million in 2022, then soared by 41.09% to $351.1 million in 2023, then increased by 6.47% to $373.9 million in 2024.